5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.
2 citations
,
July 2025 in “Advances in Therapy” Alopecia areata negatively impacts quality of life and work, even with moderate hair loss.
June 1993 in “Current opinion in therapeutic patents” Hexahydrobenzo[f]quinolines are effective at blocking the enzyme 5α-reductase.
1 citations
,
July 2023 in “Al-Azhar Medical Journal” Higher antigliadin antibodies are linked to more severe alopecia areata, suggesting screening for celiac disease in these patients.
August 1995 in “Journal of The European Academy of Dermatology and Venereology” New therapy helps treat hair loss.
September 2025 in “Tạp chí Da liễu học Việt Nam” 2.5 mg/mL TAC is as effective and safe as 5 mg/mL, but 5 mg/mL may improve hair regrowth and density more.
Liquid nitrogen cryotherapy worked well for many patients with stubborn alopecia areata.
1 citations
,
August 2022 in “Biomedicines” Dutasteride, usually used for prostate issues and hair loss, could potentially treat Amyotrophic Lateral Sclerosis (ALS) due to its neuroprotective, antioxidant, and anti-inflammatory properties, but more testing is needed.
October 2010 in “Informa Healthcare eBooks” January 2014 in “Journal of Clinical Dermatology” Topical minoxidil improves life quality for women with hair loss.
December 2024 in “eCommons - AKU (Aga Khan University)” PICAT is a reliable tool for assessing dermatology residents' skills in PRP procedures for hair loss.
Virtual healthcare significantly improves quality of life for men with hair loss if they stick to the treatment.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
October 2024 in “Canadian Journal of Health Technologies” Olumiant should be covered for severe alopecia areata if certain conditions are met.
9 citations
,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
20 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Researchers created a fast, accurate computer program to measure hair loss in alopecia areata patients.
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
19 citations
,
May 2014 in “Molecules” Avicequinone C, a compound found in the Avicennia marina plant, can reduce hair loss by inhibiting a hormone linked to androgenic alopecia.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
43 citations
,
November 2009 in “Archives of dermatology” Alefacept does not effectively treat severe alopecia areata.
August 2021 in “Journal of the American Academy of Dermatology” Oral baricitinib is effective and safe for treating alopecia areata.
May 2025 in “Anadolu Kliniği Tıp Bilimleri Dergisi” Gene variations may increase oxidative stress in male pattern baldness.
December 2021 in “Journal of Cosmetic Dermatology” Thiol/disulfide balance is normal in male AGA patients but shifts towards oxidative stress with emotional stress and low vitamin D.
13 citations
,
August 2018 in “Clinical Chemistry” Total testosterone levels can help diagnose androgen-producing tumors and hyperandrogenism in women.
March 2024 in “Healthcare” Stem cell treatment improved life quality and sexual function in women with hair loss.
December 2012 in “http://isrctn.org/>”
45 citations
,
December 2018 in “Lasers in Medical Science” LLLT promotes hair growth and improves hair density safely in men and women.
6 citations
,
January 2024 in “Journal of Cosmetic Dermatology” Alopecia areata patients have worse quality of life, anxiety, and depression than vitiligo patients.
January 2023 in “Figshare” Quality of life, overall survival, and progression-free survival should be equally prioritized in advanced breast cancer treatment decisions.
September 2022 in “Journal of Cosmetic Dermatology”